AMGN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 2289 min ago

@ $270.69

Išleistas: 26 bal. 2024 @ 22:51

Grąža: -0.26%

Ankstesnis signalas: bal. 26 - 20:55

Ankstesnis signalas: Pardavimas

Grąža: -0.03 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	2.44M
Vidutinė apimtis	2.95M
Rinkos kapitalizacija	144.69B
EPS	$0 ( 2024-04-25 )
Kita pelno data	( $3.87 ) 2024-05-31
Last Dividend	$2.25 ( 2024-02-15 )
Next Dividend	$0 ( N/A )
P/E	21.60
ATR14	$5.96 (2.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Santos Esteban	Sell	6 137	Common Stock
2024-03-18	Reese David M	Sell	6 202	Common Stock
2024-03-18	Miller Derek	Sell	475	Common Stock
2024-03-18	Khosla Rachna	Sell	438	Common Stock
2024-03-18	Grygiel Nancy A.	Sell	703	Common Stock

INSIDER POWER
58.82
Last 97 transactions
Buy: 472 102 \| Sell: 97 922

Tūris Koreliacija

Ilgas: -0.56 (weak negative)

Trumpas: -0.27 (neutral)

Signal:(30) Neutral

Amgen Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SMIT	0.929
CNCE	0.926
PLIN	0.925
CTIC	0.921
RETA	0.921
LAWS	0.921
PIII	0.917
IMTX	0.914
OP	0.913
OBT	0.912

10 Labiausiai neigiamai susiję koreliacijos
RGLD	-0.945
GRFS	-0.941
IMVT	-0.939
WB	-0.936
HCM	-0.934
HERA	-0.934
SOCL	-0.933
HOFT	-0.933
IPKW	-0.93
HERAU	-0.929

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Amgen Inc Koreliacija - Valiuta/Žaliavos

-0.09
( neutral )

0.08
( neutral )

0.00
( neutral )

0.17
( neutral )

0.23
( neutral )

-0.22
( neutral )

Amgen Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$28.19B
Bruto pelnas:	$19.74B (70.02 %)
EPS:	$12.56

FY	2023
Pajamos:	$28.19B
Bruto pelnas:	$19.74B (70.02 %)
EPS:	$12.56

FY	2022
Pajamos:	$26.32B
Bruto pelnas:	$19.92B (75.66 %)
EPS:	$12.18

FY	2021
Pajamos:	$25.98B
Bruto pelnas:	$19.53B (75.16 %)
EPS:	$10.06

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.940 (N/A)	$1.940 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.25 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Amgen Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.55 - Stable (31.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2011-08-16
Last Dividend	$2.25	2024-02-15
Next Dividend	$0	N/A
Payout Date	2024-03-07
Next Payout Date	N/A
# dividends	51	--
Total Paid Out	$61.13	--
Avg. Dividend % Per Year	2.40%	--
Score	5.46	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.55
Div. Directional Score	8.29	--

Next Divdend (Est)
(2024-07-01)

$2.30 Estimate 61.99 %

Dividend Stability

0.99 Excellent

Dividend Score

5.46

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0.560	1.01%
2012	$1.440	2.25%
2013	$1.880	2.11%
2014	$2.44	2.11%
2015	$3.16	1.98%
2016	$4.00	2.53%
2017	$4.60	3.05%
2018	$5.28	2.98%
2019	$5.80	3.02%
2020	$6.40	2.67%
2021	$7.04	3.11%
2022	$7.76	3.42%
2023	$8.52	3.26%
2024	$2.25	0.76%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.238	1.500	5.23	7.85	[0 - 0.5]
returnOnAssetsTTM	0.0691	1.200	7.70	9.23	[0 - 0.3]
returnOnEquityTTM	1.033	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0.678	-1.000	3.22	-3.22	[0 - 1]
currentRatioTTM	1.649	0.800	6.75	5.40	[1 - 3]
quickRatioTTM	1.622	0.800	5.17	4.13	[0.8 - 2.5]
cashRatioTTM	0.595	1.500	7.81	10.00	[0.2 - 2]
debtRatioTTM	0.665	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	3.15	1.000	9.94	9.94	[3 - 30]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
freeCashFlowPerShareTTM	13.76	2.00	3.12	6.24	[0 - 20]
debtEquityRatioTTM	10.37	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.700	1.000	1.663	1.663	[0.2 - 0.8]
operatingProfitMarginTTM	0.321	1.000	5.57	5.57	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.131	1.000	-0.383	-0.383	[0.2 - 2]
assetTurnoverTTM	0.290	0.800	-1.399	-1.119	[0.5 - 2]
Total Score				10.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.50	1.000	7.93	0	[1 - 100]
returnOnEquityTTM	1.033	2.50	3.34	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.76	2.00	5.41	6.24	[0 - 30]
dividendYielPercentageTTM	3.20	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
payoutRatioTTM	0.678	1.500	3.22	-3.22	[0 - 1]
pegRatioTTM	0.622	1.500	9.19	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.300	1.000	4.99	0	[0.1 - 0.5]
Total Score				6.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.